SCM
NRIX icon

Soleus Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Soleus Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.5M Sell
938,163
-281,231
-23% -$4.66M 0.59% 42
2025
Q4 		$23.1M Sell
1,219,394
-1,203,439
-50% -$17.3M 0.85% 36
2025
Q3 		$22.4M Hold
2,422,833
– – 1.13% 26
2025
Q2 		$27.6M Hold
2,422,833
– – 1.83% 16
2025
Q1 		$28.8M Buy
2,422,833
+320,000
+15% +$5.35M 2.07% 13
2024
Q4 		$39.6M Buy
2,102,833
+1,036,999
+97% +$23.8M 2.49% 12
2024
Q3 		$23.9M Sell
1,065,834
-990,082
-48% -$22.4M 1.85% 18
2024
Q2 		$42.9M Buy
2,055,916
+940,916
+84% +$14.7M 3.78% 4
2024
Q1 		$16.4M Buy
1,115,000
+972,000
+680% +$10.5M 1.22% 24
2023
Q4 		$1.48M Sell
143,000
-671,000
-82% -$4.6M 0.16% 59
2023
Q3 		$6.4M Buy
+814,000
New +$7.43M 0.59% 46
2022
Q4 		– Sell
-504,144
Closed -$6.57M – 84
2022
Q3 		$6.57M Sell
504,144
-490,348
-49% -$7.76M 0.89% 33
2022
Q2 		$12.6M Sell
994,492
-17,146
-2% -$194K 1.97% 17
2022
Q1 		$14.2M Buy
1,011,638
+268,400
+36% +$4.76M 1.83% 20
2021
Q4 		$21.5M Buy
743,238
+479,338
+182% +$14.5M 2.15% 13
2021
Q3 		$7.91M Buy
+263,900
New +$8.14M 1.23% 26

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Soleus Capital Management's NRIX Position: Q1 2026 in Review

Soleus Capital Management reduced its Nurix Therapeutics (NRIX) stake by 23% in Q1 2026, selling an estimated $4.66M and leaving 938,163 shares worth $14.5M. The position accounts for 0.59% of the portfolio, ranked #42.

Soleus Capital Management first reported a position in NRIX in Q3 2021 and has held it in 16 quarters since. The position peaked at $42.9M in Q2 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Soleus Capital Management held 938,163 shares of Nurix Therapeutics worth $14.5M as of Q1 2026.
  • Soleus Capital Management sold 281,231 Nurix Therapeutics shares in Q1 2026, an estimated $4.66M.
  • Nurix Therapeutics made up 0.59% of Soleus Capital Management's portfolio in Q1 2026, its #42 holding.
  • Soleus Capital Management first reported a position in Nurix Therapeutics in Q3 2021 and has held it in 16 quarters since.
  • Soleus Capital Management's Nurix Therapeutics position peaked at $42.9M in Q2 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.